Scroll
To Top

Archives for: March 31st, 2017

NORD Announces Honorees for the 2017 Rare Impact Awards

Written by Jennifer Huron on March 15, 2017
ria_stickypost_240x206_1

ria_jointheconversation_dateWashington, D.C., March 15, 2017—The National Organization for Rare Disorders (NORD) today announced the people, organizations, and innovators who will be honored at the 2017 Rare Impact Awards on May 18 in Washington, D.C.

The Rare Impact Awards is a… Read More

Orphan Drugs Represent 41 Percent of All New Medications

Written by Jennifer Huron on January 11, 2017

Washington, D.C., January 11, 2017—Data released by the U.S. Food and Drug Administration (FDA) show that 9 of the 22 new medications approved in 2016, or 41 percent, are orphan drugs to treat rare diseases.

“The percentage of orphan drugs approved in recent years by FDA remains high and this is welcome news for the 30… Read More

Largest-Ever Study of SYNGAP1 (MRD5), Linked to Autism, was Launched

Written by Jennifer Huron on December 23, 2016

Research study is open to participants worldwide to advance understanding and treatments for rare disease causing non-syndromic intellectual disability ranging from mild to severe with attention deficits, impulsivity, and/or mood disorders. Seventy to eighty percent of children with SYNGAP1 also have some type of epilepsy and the SYNGAP1 gene has… Read More